Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / NovoCure TRIDENT trial fails
Regulatory securities investigation

NovoCure TRIDENT trial fails

Analysis based on 20 articles · First reported Jun 25, 2026 · Last updated Jul 16, 2026

Sentiment
-30
Attention
2
Articles
20
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

NovoCure's stock price fell 20% on the trial failure, erasing significant market value. The investigation may lead to further legal costs and reputational damage, potentially affecting investor confidence in the biotech sector.

biotechnology pharmaceuticals
Event Summary

Pomerantz LLP is investigating NovoCure Limited for potential securities fraud after the company announced disappointing Phase 3 TRIDENT trial results for its Tumor Treating Fields therapy in glioblastoma. The trial failed to show statistically significant improvement in overall survival, causing NovoCure's stock to drop 20% on June 18, 2026. The investigation focuses on whether NovoCure and its officers made misleading statements.

Key Actions
100 NovoCure stock price fell
95 NovoCure reported trial did not
90 NovoCure issued press release
90 Pomerantz LLP investigating claims NovoCure
Entities Involved
stock
NovoCure
NovoCure's Phase 3 trial failed, stock dropped 20%, and it faces a securities fraud investigation.
Importance 100.0 Sentiment -60.0
priv
Pomerantz LLP
Pomerantz is investigating NovoCure for securities fraud, representing investors.
Importance 30.0 Sentiment 0.0
per
Danielle Peyton
Danielle Peyton is the contact person at Pomerantz LLP for investors interested in joining the investigation against NovoCure.
Importance 20.0 Sentiment 0.0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where NovoCure's shares are traded, and its stock price decline was observed on this exchange.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where NovoCure is listed; the event has minimal direct impact on the exchange.
Importance 10.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ Danielle Peyton
Pomerantz LLP related ↔ Nasdaq-100
Pomerantz LLP related ↔ Nasdaq
Nasdaq-100 related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.